Objective: There was a link among Level of prostate cancer (PCa), symptoms of lower urinary tract and chronic prostatitis (CP) histology, despite there was uncertainty with this clinical meaning. We pursue a retrospective analysis of existing patient’s data at a Patna based hospital to establish the link between diagnosis of PCa and role of CP.

Methods: Hospital database were used to fetch required data for patients who had undergoing prostate biopsy with all histological findings of chronic prostatitis from April 2015 to March 2019. Patients were categorised on basis of Without Chronic Prostatitis and With Chronic Prostatitis. Using univariate and multivariate analyses association between CP and PCa diagnosis was determined.

Result: 657 patients were selected whose average mean age was 68 ± 8.23 years with PSA level of 8.8±1.1 ng/ml. Entire population were categorised on basis of Without Chronic Prostatitis (N=255) and With Chronic Prostatitis (N=402). Between group’s difference of IPSS score, age, prophylactic antibiotic use, PSA, transurethral catheter at biopsy or infectious complications, alpha-blocker or 5-α-reductase inhibitor therapy and comorbidities were statistically insignificant, whereas number of cores taken, cancer diagnosis, prostate volume, suspicious digital prostate exam, previous biopsy and hospitalizations and Gleason score >=7 differences were found the be statistically significant. Protective effect between CP and diagnosis of PCa was shown by a multivariate analysis model (HR 0.14, p= <0.01).

Conclusion: This observation suggest that PCa diagnosis is inversely related to histological finding of CP.

Keywords: Prostate Biopsy; Chronic Prostatitis, Prostate Cancer.

1. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves. J Urol 1994;152:2037-42.
2. Thompson IM, Ankerst DP, Chi C, Tangen CM, Lucia MS, Feng Z, et al. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98:529-34.
3. Krieger JN, Nyberg Jr L, Nickel JC. NIH consensus definition and classification of prostatitis JAMA. 1999; 282: 236-237.
4. McNaughton Collins, M., Fowler, F.J. Jr, Elliott, D.B. et al, Diagnosing and treating chronic prostatitis (do urologists use the 4-glass test?) . Urology. 2000;55:403–407
5. Litwin, M.S., McNaughton-Collins, M., Fowler, F.J. Jr et al, The National Institutes of Health chronic prostatitis symptom index (development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network) . J Urol. 1999;162:369–375
6. Nickel, J.C., McNaughton-Collins, M., Litwin, S.M. Development and use of a validated outcome measure for prostatitis. J Clin Outcomes Manag. 2001;8:30–37
7. Nickel J: Special report on prostatitis: state of the art. Rev Urol 3: 94–98, 2001
8. Rodriguez-Covarrubias F, Gonzalez-Ramirez A, Aguilar-Davidov B, Castillejos-Molina RA, Sotomayor M, Feria-Bernal G. Extended sampling at first biopsy improves cancer detection rate: results of a prospective, randomized trial comparing 12 versus 18-core prostate biopsy. J Urol. 2011; 185: 2132-2136.
9. Aguilar DB, Castillejos MR, Sotomayor M, Feria BG, Rodriguez-Covarrubias F. A single dose of piperacillin-tazobactam for the prophylaxis of febrile complications in transrectal needle biopsy of the prostate. J Urol. 2009; 181: 802.
10. J E Elkahwaji, R J Hauke& C M Brawner. Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate. British Journal of Cancer volume 101, pages 1740–1748 (17 November 2009).
11. Nelson WG, De Marzo AM, DeWeese TL (2001) The molecular pathogenesis of prostate cancer: implications for prostate cancer prevention. Urology 57: 39–45
12. Nelson WG, De Weese TL, De Marzo AM (2002) The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 21: 3–16
13. Cheville JC, Bostwick DG (1995) Postatrophic hyperplasia of the prostate. A histologic mimic of prostatic adenocarcinoma. Am J SurgPathol 19: 1068–1076.
14. Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, Schennach H, Schäfer G, Frauscher F, Boniol M, Severi G, Robertson C, Boyle P, Tyrol Prostate Cancer Screening Group (2008) Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 101(7): 809–816
15. Ames BN, Gold LS, Willett WC (1995) The causes and prevention of cancer. Proc Nat AcadSci USA 92: 5258–5265
16. De Nunzio C, Albisinni S, Gacci M, Tubaro A. The role of inflammation in the progression of benign prostatic hyperplasia. Curr Bladder Dysfunc Rep. 2013; 8: 142-149.
17. Catalona WJ. Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Prostate Suppl. 1996;7:64–69.

Dr Khalid Mahmood

Indira Gandhi Institute of Medical Sciences Campus, D type6/4, Sheikhpura, Patna, Bihar 800014, India